Update on the management of inflammatory bowel disease: specific role of adalimumab

References

• BaumgartDCCardingSRInflammatory bowel disease: cause and immunobiologyLancet20073691627164017499605
   PubMed Web of Science ®Google Scholar
• DignassAVan AsscheGLindsayJOThe second European evidenced-based consensus on the diagnosis and management of Crohn’s disease: current managementJ Crohns Colitis20104286221122489
   PubMed Web of Science ®Google Scholar
• LichtensteinGRHanauerSBSandbornWJPractice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adultsAm J Gastroenterol200910446548319174807
   PubMed Web of Science ®Google Scholar
• TravisSPStangeEFLemannLEuropean evidenced-based consensus on the management of ulcerative colitis: current managementJ Crohn’s Colitis200822462
   Google Scholar
• KornbluthASacharDUlcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol201010550152320068560
   PubMed Web of Science ®Google Scholar
• HUMIRA^® Product monographAbbott LaboratoriesAbbott Park, IL
   Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology200613032333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut2007561232123917299059
   PubMed Web of Science ®Google Scholar
• ColombelJ-FSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology2007132526517241859
   PubMed Web of Science ®Google Scholar
• FeaganBGPanaccioneRSandbornWJEffects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM studyGastroenterology20081351493149918848553
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPComparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trialAm J Gastroenterol20091041170117919352339
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFSchreiberSDosage adjustment during long-term adalimumab treatment for Crohn’s disease:clinical efficacy and pharmacoeconomicsInflamm Bowel Dis20111714115120848500
   PubMed Web of Science ®Google Scholar
• PanaccioneRColombelJFSandbornWJAdalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s diseaseAliment Pharmacol Ther2010311296130920298496
   PubMed Web of Science ®Google Scholar
• LofbergRLouisEReinischWAdalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CAREInflamm Bowel Dis2011 [Epub ahead of print].
   Web of Science ®Google Scholar
• BillioudVSandbornWJPeyrin-BirouletLLoss of response and need for Adalimumab dose intensification in Crohn’s disease: a systematic reviewAm J Gastroenterol201110667468421407178
   PubMed Web of Science ®Google Scholar
• ColombelJFSchwartsDASandbornWJAdalimumab for the treatment of fistulas in patients with Crohn’s diseaseGut20095894094819201775
   PubMed Web of Science ®Google Scholar
• LichtigerSBinionDGWolfDCThe CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapyAliment Pharmacol Ther2010321228123920955442
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialAnn Intern Med200714682983817470824
   PubMed Web of Science ®Google Scholar
• PanaccioneRSandbornWJD’HaensGAdalimumab maintains long-term remission in moderately to severely active Crohn’s disease after infliximab failure: 1-year follow-up of GAIN trial. [abstract]Gastroenterology2008134A133
   Web of Science ®Google Scholar
• MaCPanaccioneRHeitmanSJSystematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximabAliment Pharmacol Ther2009153097798619681810
   PubMed Web of Science ®Google Scholar
• ColombelJFRutgeertsPSandbornWJDeep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: results from EXTEND [abstract]J Crohns Colitis20104S10
   Google Scholar
• ColombelJFRutgeertsPSandbornWJDeep remission predicts long-term outcomes for Adalimumab-treated patients with Crohn’s disease: data from EXTEND [abstract]Gut201059Suppl 3A80
   Google Scholar
• RoshJRLererTMarkowitzJRetrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric crohn’s diseaseAm J Gastroenterol20091043042304919724267
   PubMed Web of Science ®Google Scholar
• RussellRKWilsonMLLoganathanSA British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel diseaseAliment Pharmacol Ther20113394695321342211
   PubMed Web of Science ®Google Scholar
• HyamsJSGriffithsAMMarkowitzJInduction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn’s disease in children [abstract]Gastroenterology2011140Suppl 1S90
   Google Scholar
• Peyrin-BirouletLLaclotteCRoblinXAdalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label studyWorld J Gastroenterol2007132328233217511032
   PubMed Web of Science ®Google Scholar
• OussalahALaclotteCChevauxJBLong-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experienceAliment Pharmacol Ther20082896697218652603
   PubMed Web of Science ®Google Scholar
• AfifWLeightonJAHanauerSBOpen-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximabInflamm Bowel Dis2009151302130719408340
   PubMed Web of Science ®Google Scholar
• GiesNKroekerKIWongKTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohortAliment Pharmacol Ther20103252252820500733
   PubMed Web of Science ®Google Scholar
• TaxoneraCEstellésJBlancoIAdalimumab for ulcerative colitis patients previously treated with infliximab: outcomes at short and long term and predictors of responseAliment Pharmacol Ther20113334034821133961
   PubMed Web of Science ®Google Scholar
• HudisNRajcaBPolyakSThe outcome of active ulcerative colitis treated with adalimumab [abstract]Gastroenterology2009136A661
   Web of Science ®Google Scholar
• García-BoschOAceitunoMPerezJEfficacy of adalimumab in the treatment of ulcerative colitis [abstract]J Crohns Colitis20104S55
   Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut20116078078721209123
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJKumarA52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosoppresants [abstract]J Crohns Colitis20115S10
   Google Scholar
• SandbornWJVan AsscheGThakkarRBAdalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis [abstract]J Crohns Colitis20115S87
   Google Scholar
• SandbornWJVan AsscheGAReinischWInduction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis [abstract]Gastroenterology20111405 Suppl 1S123S124
   Web of Science ®Google Scholar
• ColombelJFSandbornWJPanaccioneRAdalimumab safety in global clinical trials of patients with Crohn’s diseaseInflamm Bowel Dis2009151308131919434735
   PubMed Web of Science ®Google Scholar
• ShaleMJSeowCHCoffinSReview article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel diseaseAliment Pharmacol Ther201031203419681818
   PubMed Web of Science ®Google Scholar
• CottoneMKohnADapernoMAdvanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel diseaseClin Gastroenterol Hepatol20119303520951835
   PubMed Web of Science ®Google Scholar
• FiorinoGAllezMMalesciAReview article: TNFα induced psoriasis in patients with inflammatory bowel diseaseAliment Pharmacol Ther20092992192719210297
   PubMed Web of Science ®Google Scholar
• KarmirisKPaintaudGNomanMInfluence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s diseaseGastroenterology20091371628164019664627
   PubMed Web of Science ®Google Scholar
• MahadevanUMillerJKWolfDCAdalimumab levels detected in cord blood and infants exposed in utero [abstract]Gastroenterology20111405 Suppl 1S61S62
   Web of Science ®Google Scholar
• JohnsonDLJonesKLChambersCDPregnancy outcome in women exposed to adalimumab: the OTIS autoimmune disease in pregnancy project [abstract]Gastroenterology20091365 Suppl 1A27
   Web of Science ®Google Scholar
• MarchioniRMKernerCLichtensteinGRAnti-TNF therapy and fetal risk: a systematic review of the literature [abstract]Gastroenterology20111405 Suppl 1S772
   Web of Science ®Google Scholar
• Ben-HorinSYavzoriMKatzLAdalimumab level in breast milk of a nursing motherClin Gastroenterol Hepatol2010847547620005982
   PubMed Web of Science ®Google Scholar
• D’HaensGBaertFVan AsscheGBelgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trialLancet200837166066718295023
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med20103621383139520393175
   PubMed Web of Science ®Google Scholar
• van der ValkMEvan OijenMGSiersemaPDCrohn’s disease patients treated with adalimumab benefit from co-treatment with immunomodulators: results from a nationwide study in the Netherlands [abstract]Gastroenterology20111405 Suppl 1S264
   Web of Science ®Google Scholar